Developer docs
API playgroundTry for free, no card

Search company profiles

Morepen Laboratories

Full company profile

uuid0006u6c

Namestring
Morepen Laboratories
Legal namestring
Morepen Laboratories Limited
Websiteurl
morepen.com
Company typeenum
Public
Founded yearint
1984
Descriptiontext

Morepen Laboratories Limited is an Indian pharmaceutical manufacturer founded in 1984 and headquartered in Gurgaon, with integrated manufacturing operations at Baddi and Masulakhanna in Himachal Pradesh across 10 purpose-built plants and capacity expanding toward 800 KL. The company operates in four business segments: (1) Active Pharmaceutical Ingredients (APIs), where it is the largest global producer of Montelukast at 45MT per annum and holds over 90% US market share of generic Loratadine at 120MT, with USFDA, WHO GMP, and EU GMP certified facilities supplying exports to over 80 countries; (2) Home Diagnostics, where it was the first company to manufacture glucometers and strips in India, with an installed base of approximately 4 million glucose monitors and 450 million strips sold; (3) Dr. Morepen branded OTC and consumer healthcare products, comprising 400+ SKUs including the 70-year-old Burnol and 40-year-old Lemolate brands, reaching over 100 million consumers; and (4) Finished Formulations spanning 150+ SKUs across cardiac, diabetic, and multispecialty categories. The company was carved out from a pure-play API exporter via a USD 100 million investment from Corinth Group of Switzerland in April 2021, a Rs 200 crore QIP in August 2024, the medical devices business carve-out into a wholly-owned subsidiary, and most recently a landmark Rs 825 crore (~USD 91 million) multi-year CDMO contract from a leading global pharma major that marks a strategic pivot from spot API supply toward long-term structured contract manufacturing programs. Its go-to-market combines direct enterprise sales for API and CDMO customers, a 2,000+ distributor domestic network for diagnostics and OTC products, and direct-to-consumer channels via the Dr. Morepen Pharmacy and Sync mobile applications.

Short descriptiontext

Morepen Laboratories is an Indian pharmaceutical manufacturer producing APIs (Montelukast, Loratadine, Atorvastatin), home diagnostics, branded OTC products, and finished formulations, exporting to over 80 countries and serving 100+ million domestic consumers under the Dr. Morepen brand, with a recent pivot into CDMO services via a Rs 825 crore multi-year contract.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersGurugram, India
HQ citystring
Gurugram
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Active Pharmaceutical Ingredients, Generic Drug Manufacturing, Home Diagnostic Devices, Contract Development Manufacturing, OTC Healthcare Products
Industry3 codes
PRIMARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Pharmaceutical Manufacturing
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Active Pharmaceutical Ingredients (API)
TypeOne Time License
Description

Bulk drug API production and export to regulated markets. The company is a global leader with USFDA-approved facilities. Key products include Montelukast, Loratadine, and Atorvastatin. Exports currently account for 70% of API business, expected to rise to 80% over three years.

morepen.com
2Contract Development and Manufacturing (CDMO)
TypeOne Time License
Description

Multi-year CDMO mandates from global pharma majors. Secured Rs 825 crore CDMO contract from leading global pharma company, expected to execute within 12-15 months. Represents strategic shift from spot business to long-term structured customer programmes.

morepen.com
3Home Diagnostics
TypeHardware Sales
Description

Self-care products including BP Monitors, Glucose Monitors, Nebulizers, Thermometers, weighing scales and steamers. Sales through large distribution network in India.

morepen.com
4OTC & Healthcare Products
TypeOne Time License
Description

Over 400+ OTC products under Dr. Morepen brand including flagship products Burnol (70-year legacy, market leader) and Lemolate (40-year brand). Products available through pharmacy app and retail channels.

morepen.com
5Finished Formulations
TypeOne Time License
Description

High quality generic medicines for multispecialty, cardiac and diabetic categories through dedicated business units having 150+ SKUs. Integrated manufacturing facilities for contract manufacturing requirements.

morepen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Stock trading recommendation - Buy at ₹49, target ₹53
ModelOtherBilling cadencePay-as-you-go
Notes

Stock recommendation from Prabhudas Lilladher analyst for intraday trading purposes.

livemint.com
2OTC products pricing under Dr. Morepen brand
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Dr. Morepen Pharmacy App delivers up to 50% off on quality branded medicines. 'Thank You' multivitamin pack priced at ₹499 for 1-year supply.

morepen.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Burnol
Description

Original Burns Cream with 70-year legacy, market leader in burn treatment category in India

morepen.com
+4 more records
Core offering1 text field

Morepen Laboratories manufactures and exports Active Pharmaceutical Ingredients (APIs) such as Montelukast, Loratadine, and Atorvastatin from USFDA-approved facilities. The company also produces home diagnostic devices (glucometers, BP monitors), over 400 OTC healthcare products under the Dr. Morepen and Gubb World brands, finished generic formulations, and offers Contract Development and Manufacturing (CDMO) services to global pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 69% year-on-year net profit increase to ₹20 crore in Q4 FY26
+4 more records
Product overview1 text field

Morepen Laboratories is a diversified pharmaceutical company with four core business segments: Active Pharmaceutical Ingredients (APIs), Home Diagnostics, Dr. Morepen OTC products, and Finished Formulations. The company operates USFDA-approved manufacturing facilities and exports to over 80 countries. Its API division is a global leader in Montelukast and Loratadine production, while its consumer health division under Dr. Morepen and Gubb World brands serves over 100 million consumers with 400+ OTC products. The company has recently expanded into contract development and manufacturing (CDMO) services with a landmark ₹825 crore mandate, and into digital health with mobile applications for health monitoring and pharmacy services.

Product and service8 records
1Active Pharmaceutical Ingredients (APIs)
CategoryActive Pharmaceutical Ingredients
Description

Bulk drug APIs production with USFDA-approved facilities. Key products include Montelukast (largest global producer, 45MT annual capacity), Loratadine (over 90% US market share, 120MT capacity), Atorvastatin (top manufacturer in blockbuster US$18bn market), and Fexofenadine Hydrochloride (USFDA-approved generic Allegra). Exported to over 80 countries with USFDA, WHO GMP, and EU GMP certifications.

2Home Diagnostics
CategoryHome Diagnostic Devices
Description

Self-care diagnostic products including Blood Glucose Monitors (4 million installed base, 450 million strips sold), BP Monitors, Nebulizers, Thermometers, weighing scales, and steamers. Marketed under Dr. Morepen brand with ISO-13485 certified manufacturing.

3Dr. Morepen OTC Healthcare Products
CategoryOver-the-Counter Healthcare Products
Description

Over 400 OTC products under Dr. Morepen brand including flagship Burnol (70-year-old burns cream and market leader), Lemolate (40-year cough & cold brand), and a wide range of healthcare, grooming, and wellness products serving over 100 million consumers.

4Finished Formulations
CategoryGeneric Pharmaceutical Formulations
Description

High-quality generic medicines for multispecialty, cardiac, and diabetic categories through dedicated business units with 150+ SKUs. Integrated manufacturing facilities support contract manufacturing requirements for global customers.

5CDMO Services
CategoryContract Development and Manufacturing
Description

Contract Development and Manufacturing Organization services for global pharmaceutical majors, leveraging USFDA-approved facilities and integrated manufacturing infrastructure. Represents a strategic shift from spot business to structured long-term customer programmes.

6Empamore
CategoryGeneric Pharmaceutical Formulations
Description

New pharmaceutical product for Type 2 Diabetes, heart failure, and kidney disease launched at 90% lower cost than existing options in the Indian market.

7LightLife by Dr. Morepen
CategoryWellness and Nutrition
Description

Weight management wellness product developed in partnership with OptiBiotix, providing a scientific approach to long-lasting weight management for Indian consumers.

8Intelicaps Probiotic Technology
CategoryProbiotic Delivery Technology
Description

Proprietary Intelicaps technology for enhanced probiotic delivery, first time introduced in India. Used as a differentiated delivery platform for probiotic products.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1VIT Bhopal
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Dr. Morepen partnered with VIT Bhopal to establish a modern health centre for 17,000+ students and faculty, providing healthcare services and products to the university community.

morepen.com
2Leading Global Pharma Major (CDMO)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-23
Description

Rs 825 crore multi-year CDMO contract - one of the largest in company's history. Strategic shift from spot business to long-term structured customer programmes. Supplies expected to begin within 4-5 months.

ndtvprofit.com
3OptiBiotix
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-20
Description

Dr. Morepen partnered with OptiBiotix to deliver safe, science-backed weight management solution to India. Launched LightLife wellness product for weight management.

morepen.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-06
Description

Partnership for test batch manufacturing of Sputnik V COVID-19 vaccine in India at Himachal Pradesh facility. Technology transfer underway with RDIF.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1Sun Pharmaceutical Industries
TypeBroad incumbent
Description

Largest Indian pharma with extensive API, generics and specialty portfolio. A larger incumbent operating across all of Morepen's segments; not a pure peer but provides the upper bound on Indian pharma scale and competitive pressure.

TypeDirect peer
Description

Major Indian pharma with large OTC and domestic formulations presence alongside global API and generics. Comparable India consumer health channel and bulk drug positioning.

TypeDirect peer
Description

Indian API and CDMO manufacturer focused on anti-retroviral, cardiovascular and oncology APIs with strong USFDA compliance. Comparable scale and business mix in API + contract manufacturing.

TypeDirect peer
Description

Indian pharma with API manufacturing, generics and specialty formulations. Comparable CDMO activity and emerging markets distribution.

TypeDirect peer
Description

Indian generic pharma with substantial API manufacturing, USFDA-approved plants, and global exports. Comparable regulatory compliance, US generics exposure, and India formulations business.

TypeDirect peer
Description

Indian pharmaceutical major with API manufacturing, generic formulations, and OTC presence across India and global markets. Comparable in CDMO activity, USFDA-compliant manufacturing, and integrated business model.

TypeDirect peer
Description

Indian pharma with API, formulations, CDMO and consumer health businesses. Overlapping product categories in cardiac, diabetes and OTC consumer health.

TypeDirect peer
Description

Indian pharma with focus on cardiac, diabetes and CNS generics plus API manufacturing. Comparable therapeutic area focus and chronic-disease franchise emphasis.

TypeDirect peer
Description

Large Indian generic pharma and API manufacturer with USFDA-approved facilities, similar product mix spanning APIs, formulations, and exports to regulated markets. Directly comparable in scale, regulatory positioning, and customer overlap.

TypeDirect peer
Description

India-headquartered pure-play API and custom synthesis (CDMO) specialist with strong USFDA track record. Most directly comparable to Morepen's API and CDMO businesses given technology and customer overlap.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Morepen Laboratories

Pharmaceutical Manufacturingmorepen.com

Morepen Laboratories is an Indian pharmaceutical manufacturer producing APIs (Montelukast, Loratadine, Atorvastatin), home diagnostics, branded OTC products, and finished formulations, exporting to over 80 countries and serving 100+ million domestic consumers under the Dr. Morepen brand, with a recent pivot into CDMO services via a Rs 825 crore multi-year contract.

What Morepen Laboratories does

Morepen Laboratories Limited is an Indian pharmaceutical manufacturer founded in 1984 and headquartered in Gurgaon, with integrated manufacturing operations at Baddi and Masulakhanna in Himachal Pradesh across 10 purpose-built plants and capacity expanding toward 800 KL. The company operates in four business segments: (1) Active Pharmaceutical Ingredients (APIs), where it is the largest global producer of Montelukast at 45MT per annum and holds over 90% US market share of generic Loratadine at 120MT, with USFDA, WHO GMP, and EU GMP certified facilities supplying exports to over 80 countries; (2) Home Diagnostics, where it was the first company to manufacture glucometers and strips in India, with an installed base of approximately 4 million glucose monitors and 450 million strips sold; (3) Dr. Morepen branded OTC and consumer healthcare products, comprising 400+ SKUs including the 70-year-old Burnol and 40-year-old Lemolate brands, reaching over 100 million consumers; and (4) Finished Formulations spanning 150+ SKUs across cardiac, diabetic, and multispecialty categories. The company was carved out from a pure-play API exporter via a USD 100 million investment from Corinth Group of Switzerland in April 2021, a Rs 200 crore QIP in August 2024, the medical devices business carve-out into a wholly-owned subsidiary, and most recently a landmark Rs 825 crore (~USD 91 million) multi-year CDMO contract from a leading global pharma major that marks a strategic pivot from spot API supply toward long-term structured contract manufacturing programs. Its go-to-market combines direct enterprise sales for API and CDMO customers, a 2,000+ distributor domestic network for diagnostics and OTC products, and direct-to-consumer channels via the Dr. Morepen Pharmacy and Sync mobile applications.

Morepen Laboratories firmographics

Firmographics
Name
Morepen Laboratories
Legal name
Morepen Laboratories Limited
Website
https://morepen.com
Company type
Public
Founded year
1984
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Morepen Laboratories is an Indian pharmaceutical manufacturer producing APIs (Montelukast, Loratadine, Atorvastatin), home diagnostics, branded OTC products, and finished formulations, exporting to over 80 countries and serving 100+ million domestic consumers under the Dr. Morepen brand, with a recent pivot into CDMO services via a Rs 825 crore multi-year contract.
Ownership category
akta.pro rank

Morepen Laboratories industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing

Keywords

  • Active Pharmaceutical Ingredients
  • Generic Drug Manufacturing
  • Home Diagnostic Devices
  • Contract Development Manufacturing
  • OTC Healthcare Products

Where Morepen Laboratories is headquartered

Location

Headquarters

HQ city
Gurugram
HQ country
India
HQ region
Asia

Offices2 records

Markets served

Morepen Laboratories business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Active Pharmaceutical Ingredients (API): Bulk drug API production and export to regulated markets. The company is a global leader with USFDA-approved facilities. Key products include Montelukast, Loratadine, and Atorvastatin. Exports currently account for 70% of API business, expected to rise to 80% over three years.
  2. Contract Development and Manufacturing (CDMO): Multi-year CDMO mandates from global pharma majors. Secured Rs 825 crore CDMO contract from leading global pharma company, expected to execute within 12-15 months. Represents strategic shift from spot business to long-term structured customer programmes.
  3. Home Diagnostics: Self-care products including BP Monitors, Glucose Monitors, Nebulizers, Thermometers, weighing scales and steamers. Sales through large distribution network in India.
  4. OTC & Healthcare Products: Over 400+ OTC products under Dr. Morepen brand including flagship products Burnol (70-year legacy, market leader) and Lemolate (40-year brand). Products available through pharmacy app and retail channels.
  5. Finished Formulations: High quality generic medicines for multispecialty, cardiac and diabetic categories through dedicated business units having 150+ SKUs. Integrated manufacturing facilities for contract manufacturing requirements.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goStock trading recommendation - Buy at ₹49, target ₹53
Unit PricingPay-as-you-goOTC products pricing under Dr. Morepen brand

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Morepen Laboratories product offering

Product offering

Core offering

Morepen Laboratories manufactures and exports Active Pharmaceutical Ingredients (APIs) such as Montelukast, Loratadine, and Atorvastatin from USFDA-approved facilities. The company also produces home diagnostic devices (glucometers, BP monitors), over 400 OTC healthcare products under the Dr. Morepen and Gubb World brands, finished generic formulations, and offers Contract Development and Manufacturing (CDMO) services to global pharmaceutical companies.

Product overview

Morepen Laboratories is a diversified pharmaceutical company with four core business segments: Active Pharmaceutical Ingredients (APIs), Home Diagnostics, Dr. Morepen OTC products, and Finished Formulations. The company operates USFDA-approved manufacturing facilities and exports to over 80 countries. Its API division is a global leader in Montelukast and Loratadine production, while its consumer health division under Dr. Morepen and Gubb World brands serves over 100 million consumers with 400+ OTC products. The company has recently expanded into contract development and manufacturing (CDMO) services with a landmark ₹825 crore mandate, and into digital health with mobile applications for health monitoring and pharmacy services.

Differentiator

Problem solved

Functional benefit

Brands

  • Burnol: Original Burns Cream with 70-year legacy, market leader in burn treatment category in India
  • Lemolate
  • LightLife
  • Empamore
  • Intelicaps

Products and services

  • Active Pharmaceutical Ingredients (APIs) Bulk drug APIs production with USFDA-approved facilities. Key products include Montelukast (largest global producer, 45MT annual capacity), Loratadine (over 90% US market share, 120MT capacity), Atorvastatin (top manufacturer in blockbuster US$18bn market), and Fexofenadine Hydrochloride (USFDA-approved generic Allegra). Exported to over 80 countries with USFDA, WHO GMP, and EU GMP certifications.
  • Home Diagnostics Self-care diagnostic products including Blood Glucose Monitors (4 million installed base, 450 million strips sold), BP Monitors, Nebulizers, Thermometers, weighing scales, and steamers. Marketed under Dr. Morepen brand with ISO-13485 certified manufacturing.
  • Dr. Morepen OTC Healthcare Products Over 400 OTC products under Dr. Morepen brand including flagship Burnol (70-year-old burns cream and market leader), Lemolate (40-year cough & cold brand), and a wide range of healthcare, grooming, and wellness products serving over 100 million consumers.
  • Finished Formulations High-quality generic medicines for multispecialty, cardiac, and diabetic categories through dedicated business units with 150+ SKUs. Integrated manufacturing facilities support contract manufacturing requirements for global customers.
  • CDMO Services Contract Development and Manufacturing Organization services for global pharmaceutical majors, leveraging USFDA-approved facilities and integrated manufacturing infrastructure. Represents a strategic shift from spot business to structured long-term customer programmes.
  • Empamore New pharmaceutical product for Type 2 Diabetes, heart failure, and kidney disease launched at 90% lower cost than existing options in the Indian market.
  • LightLife by Dr. Morepen Weight management wellness product developed in partnership with OptiBiotix, providing a scientific approach to long-lasting weight management for Indian consumers.
  • Intelicaps Probiotic Technology Proprietary Intelicaps technology for enhanced probiotic delivery, first time introduced in India. Used as a differentiated delivery platform for probiotic products.

Quantifiable outcome

  • 69% year-on-year net profit increase to ₹20 crore in Q4 FY26
  • +4 more outcomes

Companies that use Morepen Laboratories

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Morepen Laboratories technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Morepen Laboratories partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and flagship.

  • VIT BhopalcoreStrategic or Co-development Partner · 1 June 2026Dr. Morepen partnered with VIT Bhopal to establish a modern health centre for 17,000+ students and faculty, providing healthcare services and products to the university community.
  • Leading Global Pharma Major (CDMO)flagshipStrategic or Co-development Partner · 23 February 2026Rs 825 crore multi-year CDMO contract - one of the largest in company's history. Strategic shift from spot business to long-term structured customer programmes. Supplies expected to begin within 4-5 months.
  • OptiBiotixcoreStrategic or Co-development Partner · 20 March 2024Dr. Morepen partnered with OptiBiotix to deliver safe, science-backed weight management solution to India. Launched LightLife wellness product for weight management.
  • Russian Direct Investment Fund (RDIF)coreStrategic or Co-development Partner · 6 July 2021Partnership for test batch manufacturing of Sputnik V COVID-19 vaccine in India at Himachal Pradesh facility. Technology transfer underway with RDIF.

Scale indicators12 records

Recent moves7 records

Expansion highlights7 records

Morepen Laboratories competitors and assessment

Company assessment

Broad incumbents

  • Sun Pharmaceutical Industries: Largest Indian pharma with extensive API, generics and specialty portfolio. A larger incumbent operating across all of Morepen's segments; not a pure peer but provides the upper bound on Indian pharma scale and competitive pressure.

Direct peers

  • Cipla Limited: Major Indian pharma with large OTC and domestic formulations presence alongside global API and generics. Comparable India consumer health channel and bulk drug positioning.
  • Laurus Labs: Indian API and CDMO manufacturer focused on anti-retroviral, cardiovascular and oncology APIs with strong USFDA compliance. Comparable scale and business mix in API + contract manufacturing.
  • Glenmark Pharmaceuticals: Indian pharma with API manufacturing, generics and specialty formulations. Comparable CDMO activity and emerging markets distribution.
  • Lupin Limited: Indian generic pharma with substantial API manufacturing, USFDA-approved plants, and global exports. Comparable regulatory compliance, US generics exposure, and India formulations business.
  • Dr. Reddy's Laboratories: Indian pharmaceutical major with API manufacturing, generic formulations, and OTC presence across India and global markets. Comparable in CDMO activity, USFDA-compliant manufacturing, and integrated business model.
  • Zydus Lifesciences (Cadila Healthcare): Indian pharma with API, formulations, CDMO and consumer health businesses. Overlapping product categories in cardiac, diabetes and OTC consumer health.
  • Torrent Pharmaceuticals: Indian pharma with focus on cardiac, diabetes and CNS generics plus API manufacturing. Comparable therapeutic area focus and chronic-disease franchise emphasis.
  • Aurobindo Pharma: Large Indian generic pharma and API manufacturer with USFDA-approved facilities, similar product mix spanning APIs, formulations, and exports to regulated markets. Directly comparable in scale, regulatory positioning, and customer overlap.
  • Divis Laboratories: India-headquartered pure-play API and custom synthesis (CDMO) specialist with strong USFDA track record. Most directly comparable to Morepen's API and CDMO businesses given technology and customer overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Morepen Laboratories social profiles

Digital presence

Morepen Laboratories compliance and trust

Trust signal

Compliance4 records

Morepen Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Morepen Laboratories leadership team

Management profile

Number of profiles

Profiles1 record

Morepen Laboratories subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Morepen Laboratories funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Morepen Laboratories M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Morepen Laboratories

What does Morepen Laboratories do?

Morepen Laboratories manufactures and exports Active Pharmaceutical Ingredients (APIs) such as Montelukast, Loratadine, and Atorvastatin from USFDA-approved facilities. The company also produces home diagnostic devices (glucometers, BP monitors), over 400 OTC healthcare products under the Dr. Morepen and Gubb World brands, finished generic formulations, and offers Contract Development and Manufacturing (CDMO) services to global pharmaceutical companies.

Is Morepen Laboratories a public or private company?

Morepen Laboratories is a public company. It is classified as public and is currently operating.

When was Morepen Laboratories founded?

Morepen Laboratories was founded in 1984. It employs 1,001 to 5,000 people.

Where is Morepen Laboratories based?

Morepen Laboratories is headquartered in Gurugram, India, in the Asia region.

How does Morepen Laboratories make money?

Five revenue lines are on record. Active Pharmaceutical Ingredients (API) is the primary driver. The others are contract Development and Manufacturing (CDMO), home Diagnostics, OTC & Healthcare Products and finished Formulations.

Who are Morepen Laboratories's main competitors?

Sun Pharmaceutical Industries is listed as a broad incumbent. Direct peers are Cipla Limited, Laurus Labs, Glenmark Pharmaceuticals, Lupin Limited, Dr. Reddy's Laboratories, Zydus Lifesciences (Cadila Healthcare), Torrent Pharmaceuticals, Aurobindo Pharma and Divis Laboratories.

Does Morepen Laboratories have an API?

No public API is recorded for Morepen Laboratories.

What industry is Morepen Laboratories in?

Morepen Laboratories's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAG, Generic APIs & Intermediates (Active Ingredients), with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Machine MakerMorepen Laboratories Enters US Prescription Generics Market with Desloratadine LaunchMorepen Laboratories launched its first US prescription generic, Desloratadine Tablets USP 5 mg, via its US subsidiary Morepen Bio Inc. The company also submitted an FDA ANDA for Sitagliptin Phosphate Tablets, and plans further US generic filings and distribution.https://www.outlookbusiness.com/Morepen Enters U.S. Prescription Generics Market With The Launch Of Its Desloratadine Tablets, Complementing Broader API, R&D And CDMO Growth Strategy – Outlook BusinessMorepen Laboratories launched its first U.S. prescription generic, Desloratadine Tablets USP 5 mg, via its U.S. arm Morepen Bio Inc. The company has supplied Desloratadine API to U.S. customers for years, and the launch builds on its API and CDMO business. It also submitted an FDA ANDA for Sitagliptin Phosphate Tablets, with further U.S. generic filings planned.https://www.outlookbusiness.com/Morepen Enters U.S. Prescription Generics Market With The Launch Of Its Desloratadine Tablets, Complementing Broader API, R&D And CDMO Growth Strategy – Outlook BusinessMorepen Laboratories launched its first U.S. prescription generic, Desloratadine Tablets USP 5 mg, via its U.S. arm Morepen Bio Inc. The company has supplied Desloratadine API to U.S. customers for years, and the launch extends into finished-dosage distribution. Morepen also submitted an FDA ANDA for Sitagliptin Phosphate Tablets, with additional U.S. generic filings planned.The Times of IndiaMorepen Laboratories launches Desloratadine (Rx) generic drug product in US marketMorepen Laboratories launched a Desloratadine generic drug product in the US market in 100-count and 500-count packs. The company also submitted its first FDA ANDA for Sitagliptin Phosphate Tablets, which is under regulatory review.ScanXMorepen Laboratories FY26 Results: standalone sales up 8.39% to ₹1,677 croreMorepen Laboratories reported standalone sales growth of 8.39% to ₹1,677 crore in FY26, with consolidated total income at ₹1,827 crore. The Medical Devices segment grew 20.13% to ₹5,970 crore, and new molecules contributed ₹5,637 crore, up 121% YoY. The company secured a multi-year CDMO mandate valued at approximately ₹825 crore.MintStocks under ₹100: Sumeet Bagadia recommends three shares to buy on Monday - 17 August 2026 | Stock Market NewsSumeet Bagadia, Executive Director at Choice Broking, recommended three stocks under ₹100 for purchase on August 17, 2026: U. Y. Fincorp, Morepen Laboratories, and Fineotex Chemical. This recommendation comes as the Indian stock market closed the week in negative territory due to elevated crude oil prices and geopolitical concerns.Business News TodayMorepen Lab Standalone June 2026 Net Sales at Rs 541.04 crore, up 38.27% Y-o-Y- Moneycontrol.comMorepen Laboratories reported standalone quarterly financial results for June 2026, with net sales growing 38.27% year-over-year to Rs 541.04 crore. Net profit surged 569.85% to Rs 54.00 crore from Rs 8.06 crore in June 2025, while EBITDA increased 268.53% to Rs 84.91 crore. EPS rose to Rs 0.99 from Rs 0.15 in the same period last year.NDTV ProfitMarket Watch: Top 10 Stocks That Soared And Slumped Today - Check ListStock market activity on Wednesday was driven by stock-specific movements with some auto, consumer, healthcare, and industrial stocks gaining sharply, while technology and specialty chemical stocks declined. Ask Automotive and Morepen Laboratories were among the top gainers, whereas Best Agrolife was the biggest loser.TradingViewMorpean Laboratories for NSE:MOREPENLAB by Microcap_InvestorMorepen Laboratories Limited saw a stock price increase on the NSE with a closing price of 69.18, reflecting a gain of 12.14 (+21.28%). This movement suggests increased investor interest in the company during the reported period.Indian Economic ObserverMorepen Clocks Highest-Ever Quarterly Revenue and Earnings in Q1'FY27; EBITDA Grows by 207% and PAT by 394%; CDMO Enters Full Scale CommercializationMorepen Laboratories Limited reported its highest-ever quarterly revenue of Rs. 575.31 Cr and earnings for Q1 FY27, with EBITDA growing 207% year-on-year to Rs. 87.72 Cr and PAT surging 394% year-on-year to Rs. 56.35 Cr. The company's Rs. 825 Cr CDMO mandate entered full scale commercialization phase with Rs. 58 Cr in commercial dispatches completed during the quarter, marking a strategic shift from traditional commodity APIs toward innovation-led manufacturing. Export revenue jumped 111% YoY, API business grew 31% with exports up 42%, and Morepen completed four consecutive USFDA inspections with zero Form 483 observations.